Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases, is set to present at several prominent investor conferences in September 2025. This initiative aligns with the company's commitment to engage with investors and stakeholders, highlighting its groundbreaking work in the biopharmaceutical landscape.

The conferences include the Cantor Global Healthcare Conference on September 5, 2025, where Climb Bio's executive team will participate in a fireside chat and one-on-one meetings. On September 9, 2025, they will attend the Baird Global Healthcare Conference, again featuring a fireside chat and opportunities for individual investor discussions. Additionally, Climb Bio will engage in one-on-one meetings at the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025. That same day, the company will also participate in the Stifel Virtual Immunology and Inflammation Forum, which will consist of a presentation alongside individual investor meetings.

Live webcasts of these presentations will be accessible through the "Investors and News" section on Climb Bio's website, with replays available two hours after each event and archived for at least 30 days.

Climb Bio's pipeline is noteworthy, featuring budoprutug, an anti-CD19 monoclonal antibody aimed at treating B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently undergoing IND-enabling studies for IgA nephropathy. This focus on innovative therapies underscores Climb Bio's dedication to addressing critical patient needs in the realm of immune-mediated disorders.

For more detailed information, interested parties can visit Climb Bio’s website or contact their Investor Relations team.

As Climb Bio, Inc. (Nasdaq: CLYM) prepares for a series of investor conferences in September 2025, investors should closely monitor the company’s developments, particularly within its promising pipeline of therapeutics targeting immune-mediated diseases. With key presentations scheduled at prestigious events such as the Cantor Global Healthcare Conference and the Baird Global Healthcare Conference, this is an opportune moment for potential investors to engage with the company and assess its long-term viability.

Climb Bio’s lead candidates, including budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody, are both demonstrating significant potential in treating B-cell mediated diseases and IgA nephropathy, respectively. The successful results from ongoing IND-enabling studies will be pivotal in determining the company's future clinical trajectory and the potential for attracting partnerships or further investment.

The format of these conferences—including both fireside chats and one-on-one meetings—provides a unique opportunity for investors to gain insights directly from Climb Bio’s executive team. This direct communication can reveal management’s strategic outlook, clinical trial timelines, and potential pathways to commercialization, which are key elements for assessment.

Market sentiment surrounding biotechnology companies can often be swayed by clinical data news, partnerships, or investor perceptions formed during such conferences. Thus, attending or following these events closely will help investors gauge market readiness for Climb Bio's candidates and identify potential investable opportunities.

Given the current trends in the biotech sector toward innovative therapies, Climb Bio’s focus on addressing unmet medical needs remains a critical growth factor. Investors should consider the holistic view of the company, including its research advancements and market positioning, before making any investment decisions ahead of these presentations.